Cost-effectiveness of a multifaceted intervention to improve quality of osteoporosis care after wrist fracture.

PubWeight™: 0.83‹?›

🔗 View Article (PMID 20878389)

Published in Osteoporos Int on September 29, 2010

Authors

S R Majumdar1, D A Lier, B H Rowe, A S Russell, F A McAlister, W P Maksymowych, D A Hanley, D W Morrish, J A Johnson

Author Affiliations

1: Department of Medicine, University of Alberta, Edmonton, AB, Canada. me2.majumdar@ualberta.ca

Associated clinical trials:

Strategies Targeting Osteoporosis to Prevent Recurrent Fractures | NCT00152321

Articles cited by this

Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res (2007) 14.84

2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ (2002) 9.89

Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med (2007) 9.83

Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med (2004) 8.86

Markov models in medical decision making: a practical guide. Med Decis Making (1994) 8.14

Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med (2007) 7.38

Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res (2000) 7.29

Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res (1992) 4.75

Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev (2002) 3.46

A practical guide for calculating indirect costs of disease. Pharmacoeconomics (1996) 3.08

Compliance with osteoporosis medications. Arch Intern Med (2005) 2.91

Economic implications of hip fracture: health service use, institutional care and cost in Canada. Osteoporos Int (2001) 2.67

A controlled trial to increase detection and treatment of osteoporosis in older patients with a wrist fracture. Ann Intern Med (2004) 2.48

Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab (2000) 2.34

Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann Intern Med (2005) 1.81

Cost effectiveness analysis in health care: contraindications. BMJ (2002) 1.80

The care gap in diagnosis and treatment of women with a fragility fracture. Osteoporos Int (2007) 1.64

Multifaceted intervention to improve diagnosis and treatment of osteoporosis in patients with recent wrist fracture: a randomized controlled trial. CMAJ (2008) 1.35

An updated systematic review of Health State Utility Values for osteoporosis related conditions. Osteoporos Int (2009) 1.31

Cost-effectiveness of the treatment and prevention of osteoporosis--a review of the literature and a reference model. Osteoporos Int (2006) 1.21

Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions. Osteoporos Int (2001) 1.18

Early assessment of the likely cost-effectiveness of a new technology: A Markov model with probabilistic sensitivity analysis of computer-assisted total knee replacement. Int J Technol Assess Health Care (2006) 1.17

Persistence, reproducibility, and cost-effectiveness of an intervention to improve the quality of osteoporosis care after a fracture of the wrist: results of a controlled trial. Osteoporos Int (2006) 1.12

Osteoporosis case manager for patients with hip fractures: results of a cost-effectiveness analysis conducted alongside a randomized trial. Arch Intern Med (2009) 1.08

Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics (2003) 1.02

Nurse case-manager vs multifaceted intervention to improve quality of osteoporosis care after wrist fracture: randomized controlled pilot study. Osteoporos Int (2010) 0.94

Recent trends in osteoporosis treatment after hip fracture: improving but wholly inadequate. J Rheumatol (2008) 0.81

Articles by these authors

(truncated to the top 100)

Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med (2009) 12.63

The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis (2009) 8.37

Factors associated with mortality in feedlot cattle: the Bruce County Beef Cattle Project. Can J Comp Med (1980) 7.74

The whiplash syndrome--common sense revisited. J Rheumatol (1997) 7.20

Interventions for preventing falls in elderly people. Cochrane Database Syst Rev (2003) 7.05

Risk of new vertebral fracture in the year following a fracture. JAMA (2001) 6.17

Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med (2000) 5.41

Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology (1993) 4.93

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis (2011) 4.78

A Vibrio cholerae pathogenicity island associated with epidemic and pandemic strains. Proc Natl Acad Sci U S A (1998) 4.75

Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther (2008) 4.54

Factors associated with mortality and treatment costs in feedlot calves: the Bruce County Beef Project, years 1978, 1979, 1980. Can J Comp Med (1982) 4.34

Factors associated with morbidity and mortality in feedlot calves: the Bruce County beef project, year two. Can J Comp Med (1981) 4.17

Evaluating the quality of systematic reviews in the emergency medicine literature. Ann Emerg Med (2001) 4.16

A bacteriophage encoding a pathogenicity island, a type-IV pilus and a phage receptor in cholera bacteria. Nature (1999) 3.89

Enterococci resistant to multiple antimicrobial agents, including vancomycin. Establishment of endemicity in a university medical center. Ann Intern Med (1995) 3.77

Canadian normative data for the SF-36 health survey. Canadian Multicentre Osteoporosis Study Research Group. CMAJ (2000) 3.77

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis (2004) 3.64

Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther (2011) 3.53

A micro-method for peripheral leucocyte migration in tuberculin sensitivity. J Clin Pathol (1971) 3.45

The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis (2009) 3.32

What is the quality of drug therapy clinical practice guidelines in Canada? CMAJ (2001) 3.15

Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med (1995) 3.11

The accuracy of patient history, wheezing, and laryngeal measurements in diagnosing obstructive airway disease. CARE-COAD1 Group. Clinical Assessment of the Reliability of the Examination-Chronic Obstructive Airways Disease. JAMA (2000) 3.10

Interventions for preventing falls in elderly people. Cochrane Database Syst Rev (2001) 3.06

Assessing the quality of randomized trials: reliability of the Jadad scale. Control Clin Trials (1999) 2.99

Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study. BMJ (2013) 2.92

Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther (2013) 2.73

Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab (2009) 2.69

The use of standardized patients in the performance of a needs assessment and development of a CME intervention in rheumatology for primary care physicians. J Rheumatol (1997) 2.67

In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci. Antimicrob Agents Chemother (1996) 2.63

Evidence-based medicine: a commentary on common criticisms. CMAJ (2000) 2.48

Disappointing longterm results with disease modifying antirheumatic drugs. A practice based study. J Rheumatol (1999) 2.45

Canadian Thoracic Society Asthma Management Continuum--2010 Consensus Summary for children six years of age and over, and adults. Can Respir J (2010) 2.42

Estimation of the prevalence of low bone density in Canadian women and men using a population-specific DXA reference standard: the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int (2000) 2.40

The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin Pharmacol Ther (2013) 2.39

Osteoporosis follow-up after wrist fractures following minor trauma. Arch Intern Med (2001) 2.36

Serum transaminases during salicylate therapy. Br Med J (1971) 2.34

The influence of osteoporotic fractures on health-related quality of life in community-dwelling men and women across Canada. Osteoporos Int (2001) 2.32

Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study. Lancet (2008) 2.30

Visceral fat and race-dependent health risks in obese nondiabetic premenopausal women. Diabetes (1997) 2.26

The capsule and O antigen in Vibrio cholerae O139 Bengal are associated with a genetic region not present in Vibrio cholerae O1. Infect Immun (1995) 2.25

The rational clinical examination. Is this patient taking the treatment as prescribed? JAMA (1993) 2.23

Practice-based research: lessons from community pharmacist participants. Pharmacotherapy (2001) 2.23

New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis (2009) 2.22

The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther (2007) 2.18

Vibrio cholerae O1 can assume a chlorine-resistant rugose survival form that is virulent for humans. J Infect Dis (1996) 2.17

An overview of interventions to improve compliance with appointment keeping for medical services. JAMA (1992) 2.13

Isolation of vancomycin-resistant enterococci from animal feed in USA. Lancet (1999) 2.12

The genetics of psoriasis. Haplotype sharing in siblings with the disease. Arch Dermatol (1990) 2.12

Distribution of Vibrio vulnificus in the Chesapeake Bay. Appl Environ Microbiol (1996) 2.10

Eu oxidation state in fluorozirconate-based glass ceramics. J Appl Phys (2009) 2.06

Thiazolidinedione use and cancer incidence in type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab (2012) 2.06

Septic arthritis. Ann Rheum Dis (1972) 2.06

Development of persistent neurologic symptoms in patients with simple neck sprain. Arthritis Care Res (1999) 2.05

A research-based guideline for appropriate use of transdermal fentanyl to treat chronic pain. Oncol Nurs Forum (1998) 2.03

Cloning and sequence of a region encoding a surface polysaccharide of Vibrio cholerae O139 and characterization of the insertion site in the chromosome of Vibrio cholerae O1. Mol Microbiol (1996) 2.01

Alternative therapies--medicine, magic, or quackery. Who is winning the battle? J Rheumatol (1997) 2.00

Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab (2000) 2.00

Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. Blood (1995) 1.99

Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int (1999) 1.98

Activation of the antioxidant response element in primary cortical neuronal cultures derived from transgenic reporter mice. J Neurochem (2002) 1.96

The McGurk effect in infants. Percept Psychophys (1997) 1.96

Thermal conductivity spectroscopy technique to measure phonon mean free paths. Phys Rev Lett (2011) 1.94

Consensus recommendations for the assessment and treatment of rheumatoid arthritis. J Rheumatol (2001) 1.93

Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clin Pharmacol Ther (1999) 1.93

Use of lumbar radiographs for the early diagnosis of low back pain. Proposed guidelines would increase utilization. JAMA (1997) 1.92

Cell-mediated immunity to herpes simplex virus in man. J Infect Dis (1974) 1.91

Ankylosing spondylitis--at the interface of bone and cartilage. J Rheumatol (2000) 1.90

Holding chambers versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst Rev (2003) 1.90

Accuracy of an electromagnetic tracking device: a study of the optimal range and metal interference. J Biomech (1996) 1.89

Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin Pharmacol Ther (2010) 1.88

Utilization of health services following spinal cord injury: a 6-year follow-up study. Spinal Cord (2004) 1.86

Evidence based management of hypertension. Cardiovascular risk factors and their effects on the decision to treat hypertension: evidence based review. BMJ (2001) 1.85

Users' guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group. JAMA (1999) 1.84

Cardiac arrest in Ontario: circumstances, community response, role of prehospital defibrillation and predictors of survival. CMAJ (1992) 1.81

Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis (2013) 1.81

Frequency of atlantoaxial subluxation and neurologic involvement in patients with ankylosing spondylitis. J Rheumatol (1995) 1.79

Interventions for preventing ankle ligament injuries. Cochrane Database Syst Rev (2001) 1.76

Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure. Diabetologia (2010) 1.76

Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database Syst Rev (2003) 1.76

Clinical and immunologic characteristics of Vibrio cholerae O139 Bengal infection in North American volunteers. J Infect Dis (1995) 1.75

Lack of congruence in the ratings of patients' health status by patients and their physicians. Med Decis Making (2001) 1.75

Relapsing invasive group B streptococcal infection in adults. Ann Intern Med (1995) 1.74

Phosphatidylinositol 3-kinase, not extracellular signal-regulated kinase, regulates activation of the antioxidant-responsive element in IMR-32 human neuroblastoma cells. J Biol Chem (2001) 1.74

Development and testing of a nonradioactive DNA oligonucleotide probe that is specific for Vibrio cholerae cholera toxin. J Clin Microbiol (1992) 1.71

A novel process for updating recommendations for managing hypertension: rationale and methods. Can J Cardiol (2000) 1.71

Antinuclear and antineutrophil cytoplasmic antibodies (ANCA) in the sera of patients with Felty's syndrome. Br J Rheumatol (1992) 1.69

Self-efficacy, psychosocial factors, and exercise behavior in traditional versus modified cardiac rehabilitation. J Cardiopulm Rehabil (2001) 1.67

Thoracoscopic neodymium: yttrium-aluminum garnet laser-assisted pulmonary resection. Ann Thorac Surg (1991) 1.67

Use of narcotic analgesics in the emergency department treatment of migraine headache. Neurology (2004) 1.66

Measuring quality of life in paediatric patients. Pharmacoeconomics (1999) 1.65

Cholera in Lima, Peru, correlates with prior isolation of Vibrio cholerae from the environment. Am J Epidemiol (1997) 1.65

Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu Rev Genomics Hum Genet (2001) 1.64

Cellular and humoral immune response of foals to vaccination with Corynebacterium equi. Can J Comp Med (1979) 1.64

The oxidation state of europium in halide glasses. J Phys Condens Matter (2011) 1.62

An open study of pentoxifylline in the treatment of severe refractory rheumatoid arthritis. J Rheumatol (1995) 1.62

Pregnancy impairs resistance of C57BL/6 mice to Leishmania major infection and causes decreased antigen-specific IFN-gamma response and increased production of T helper 2 cytokines. J Immunol (1996) 1.60

Radiographic evidence of disease progression in methotrexate treated and nonmethotrexate disease modifying antirheumatic drug treated rheumatoid arthritis patients: a meta-analysis. J Rheumatol (1992) 1.56

Cross-sectional validity of a modified Edmonton symptom assessment system in dialysis patients: a simple assessment of symptom burden. Kidney Int (2006) 1.56